Glucagon-like peptide-1 agonists (GLP-1RA, GLP-1DAs, incretin mimetics, or GLP-1 analogs) represent a category of therapeutics used in the treatment of type 2 diabetes mellitus (T2DM) and obesity
Comparative genomic mapping implicates LRRK2 for intellectual disability and autism at 12q12, and HDHD1, as well as PNPLA4, for X-linked intellectual disability at Xp22.31
BAC Water is referenced in non-clinical research settings as part of broader laboratory preparation and experimental protocols
doi:10.1074/jbc.M209372200
Rather than taking a one-size-fits-all approach, we create treatment plans that address your hormones, metabolism, and weight management goals together
People who maintain their weight loss typically report stable or improved mental health compared to their pre-treatment baseline